

Entrectinib for treating NTRK fusion-positive solid tumours

Technology appraisal guidance [TA644]

Applications to the Cancer Drugs Fund

25 June 2020 – 30 April 2025

Background

Entrectinib became available within the Cancer Drugs Fund (CDF) from 25 June 2020. This reporting period is for applications for use made between 25 June 2020 and 30 April 2025. A snapshot of the Systemic Anti-Cancer Therapy (SACT) data was taken on 2 August 2025 and made available for analysis on 20 August 2025 and includes SACT activity up to 30 April 2025.

Summary

Table 1 presents the number of applications to the CDF which were made between 25 June 2020 and 30 April 2025. We also present the number of applicants/patients with reported SACT activity and their treatment outcomes to 30 April 2025.

Table 1: Entrectinib applications made to the CDF between 25 June 2020 and 30 April 2025; SACT data to 30 April 2025.

	Numbers of patients	Comments
Applications		
Applications for new use of entrectinib: 25 June 2020 to 30 April 2025	12	Note: this is the baseline for this reporting window.
Missing in SACT		
Missing in SACT by 30 April 2025	2	
Reason for missing treatment data in SACT		
Patient died before treatment	2	Note: 2 patients died before treatment, these were confirmed by the relevant trust by the NHS England data liaison team.
Reported in SACT		
Reported in SACT by 30 April 2025	10	
Outcomes (for the 10 patients with SACT data)		
Stopped treatment: Progressive disease during chemotherapy	3	
Stopped treatment: Patient choice	1	
Patient died	2	
Patients still on treatment	4	